Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.